DNA Damage Response in Glioblastoma Mechanism for Treatment Resistance and Emerging Therapeutic Strategies

被引：9
作者：
Bonm, Alipi [1 ]
Kesari, Santosh [2 ,3 ]
机构：
[1] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[2] Pacific Neurosci Inst, Santa Monica, CA USA
[3] St Johns Canc Inst, Santa Monica, CA USA
来源：
CANCER JOURNAL | 2021年 / 27卷 / 05期
关键词：
DNA damage response; double-strand break; glioblastoma; PARP; single-strand break; GROWTH-FACTOR RECEPTOR; IONIZING-RADIATION; HOMOLOGOUS RECOMBINATION; TUMOR-CELLS; PHASE-III; KINASE; INHIBITOR; REPAIR; TEMOZOLOMIDE; EXPRESSION;
D O I：
10.1097/PPO.0000000000000540
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Glioblastoma (GBM) is an intrinsically treatment-resistant tumor and has been shown to upregulate DNA damage response (DDR) components after treatment. DNA damage response signaling mediates treatment resistance by promoting cell cycle arrest in order to allow for DNA damage repair and avoid mitotic catastrophe. Therefore, targeting the DDR pathway is an attractive strategy to combat treatment resistance in GBM. In this review, we discuss the different DDR pathways and then summarize the current preclinical evidence for DDR inhibitors in GBM, as well as completed and ongoing clinical trials.
引用
收藏
页码：379 / 385
页数：7
相关论文
共 50 条
[41]   DNA Damage Response and Growth Factor Signaling Pathways in Gliomagenesis and Therapeutic Resistance [J].
Squatrito, Massimo ;
Holland, Eric C. .
CANCER RESEARCH, 2011, 71 (18) :5945-5949
[42]   Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions [J].
Tang, Justin ;
Karbhari, Nishika ;
Campian, Jian L. .
CELLS, 2025, 14 (07)
[43]   New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs [J].
Pirlog, Bianca Oana ;
Ilut, Silvina ;
Pirlog, Radu ;
Chiroi, Paul ;
Nutu, Andreea ;
Radutiu, Delia Ioana ;
Cuc, George Daniel ;
Berindan-Neagoe, Ioana ;
Nabavi, Seyed Fazel ;
Filosa, Rosanna ;
Nabavi, Seyed Mohammad .
EXPERT REVIEWS IN MOLECULAR MEDICINE, 2023, 25
[44]   The molecular mechanism of nuclear signaling for degradation of cytoplasmic DNA: Importance in DNA damage response and cancer* [J].
Mohammadi, Erfan ;
Sadoughi, Fatemeh ;
Younesi, Simin ;
Karimian, Ansar ;
Asemi, Zatollah ;
Farsad-Akhtar, Nader ;
Jahanbakhshi, Fahime ;
Jamilian, Hamidreza ;
Yousefi, Bahman .
DNA REPAIR, 2021, 103
[45]   Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma [J].
Llaguno-Munive, Monserrat ;
Romero-Pina, Mario ;
Serrano-Bello, Janeth ;
Medina, Luis A. ;
Uribe-Uribe, Norma ;
Maria Salazar, Ana ;
Rodriguez-Dorantes, Mauricio ;
Garcia-Lopez, Patricia .
CANCERS, 2019, 11 (01)
[46]   Low mitochondrial DNA copy number is associated with poor prognosis and treatment resistance in glioblastoma [J].
Sravya, Palavalasa ;
Nimbalkar, Vidya Prasad ;
Kanuri, Nandaki Nag ;
Sugur, Harsha ;
Verma, Brijesh Kumar ;
Kundu, Paramita ;
Rao, Shilpa ;
Krishna, A. S. Uday ;
Somanna, Sampath ;
Kondaiah, Paturu ;
Arivazhagan, Arimappamagan ;
Santosh, Vani .
MITOCHONDRION, 2020, 55 :154-163
[47]   The Emerging Role of Cohesin in the DNA Damage Response [J].
Litwin, Ireneusz ;
Pilarczyk, Ewa ;
Wysocki, Robert .
GENES, 2018, 9 (12)
[48]   Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients [J].
Dalmasso, Bruna ;
Puccini, Alberto ;
Catalano, Fabio ;
Borea, Roberto ;
Iaia, Maria Laura ;
Bruno, William ;
Fornarini, Giuseppe ;
Sciallero, Stefania ;
Rebuzzi, Sara Elena ;
Ghiorzo, Paola .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (09)
[49]   Unraveling molecular signatures and prognostic biomarkers in glioblastoma: a comprehensive study on treatment resistance and personalized strategies [J].
Xue, Jinmin ;
Zhang, Jie ;
Zhu, Jing .
DISCOVER ONCOLOGY, 2024, 15 (01)
[50]   DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies [J].
Rominiyi, Ola ;
Collis, Spencer J. .
MOLECULAR ONCOLOGY, 2022, 16 (01) :11-41
12345